--- title: "Hot Pre-Market Trades in US Stocks: Liqtech Up 12.30%; Strategy Up 3.52%" type: "News" locale: "en" url: "https://longbridge.com/en/news/300574593.md" description: "Liqtech up 12.30% in pre-market trading; Strategy up 3.52%; NewGenIvf up 107.92%; Concord Biopharma up 79.41%; Lion Group Holding up 60.55%" datetime: "2026-09-30T12:43:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300574593.md) - [en](https://longbridge.com/en/news/300574593.md) - [zh-HK](https://longbridge.com/zh-HK/news/300574593.md) generator: "portal-rs" --- # Hot Pre-Market Trades in US Stocks: Liqtech Up 12.30%; Strategy Up 3.52% **Hot Pre-Market Trades in US Stocks** Liqtech rose 12.30% in pre-market trading. Based on recent key news: 1. On September 30, LiqTech International announced that its proprietary silicon carbide membrane technology supports a scalable multi-market business model, achieving strong growth in the aquaculture and marine sectors, improved profit margins, and a strengthened balance sheet. The company has set financial targets to achieve positive adjusted EBITDA by 2027 and profitability by 2028. This news boosted market confidence and drove the stock price higher. Growth in the aquaculture and marine sectors was robust. Strategy rose 3.52% in pre-market trading. Based on recent key news: 1. On September 29, the price of Bitcoin broke through $80,000, causing severe market volatility and exposing Strategy's stock to squeeze risks. Data from S3 Partners showed that capital was concentrated in shorting Bitcoin-held stocks to hedge against risk. Source: Jinse Finance 2. On September 28, Strategy provided liquidity support for bitcoin purchases by issuing additional common shares in the open market, selling approximately 1.47 million MSTR shares and raising net proceeds of $246.2 million. Source: Jinse Finance 3. On September 28, Strategy disclosed an increase in its bitcoin holdings by 1,666 BTC, bringing its total holdings to 847,666 BTC. Source: Jinse Finance. The price of Bitcoin broke through $80,000, causing market volatility. **Top Gainers in US Pre-Market Trading** NewGenIvf rose 107.92% in pre-market trading. Based on recent key news: 1. On September 29, NewGenIvf Group announced the pricing of its public offering, which is expected to generate gross proceeds of approximately $1.25 million. The offering includes 17.86 million common shares or pre-funded warrants, priced at $0.07 per share. This news drove a significant surge in the stock price. 2. On September 29, NewGenIvf Group emphasized in a press release its innovative approach in real estate development, digital asset management, and reproductive health solutions. Optimistic market expectations regarding its future growth potential further pushed the stock price higher. 3. On September 30, macroeconomic data indicated that US job openings in August decreased by 256,000 to 7.079 million, falling below market expectations. While this data may have impacted market sentiment, it did not directly affect NewGenIvf's stock price. The market reacted positively to the innovation and the public offering, driving the stock price up. Concord Biopharma rose 79.41% in pre-market trading. Based on recent key news: 1. On September 30, Concord Biopharma announced positive preliminary data from its global Phase II study. As an adjunctive therapy for COPD and acute exacerbations of type 2 inflammation, Rademikibart reduced moderate-to-severe COPD exacerbations by 85% within one month and reduced hospitalizations or emergency room visits by 100%. This news drove a significant surge in the stock price. Source: Reuters 2. On September 30, Concord Biopharma planned to engage with the FDA to advance the Phase III program for Rademikibart. This plan demonstrated the company's further development potential in the field of COPD treatment, enhancing market confidence. Source: Reuters 3. On September 30, Rademikibart showed good tolerability and a low incidence of adverse events in the Phase II study. These results boosted investor confidence in the drug's safety, further driving the stock price higher. Source: Reuters. The biopharmaceutical industry has been active recently, with noticeable capital inflows. Lion Group Holding rose 60.55% in pre-market trading. Based on recent key news: 1. On September 29, Lion Group Holding released an important announcement via the EDGAR system, concerning its financing arrangements and capital market strategy. This announcement attracted market attention and drove a significant surge in the stock price. 2. On September 29, the company's financing arrangements with institutional investors, including securities purchase agreements and bond issuances, demonstrated its emphasis on capital market-driven funding strategies. These instruments are closely aligned with the demands of US investors, further boosting market interest in its stock. 3. On September 29, technical sentiment indicators signaled a sell, but the market's positive reaction to the financing announcement offset this negative signal, resulting in a significant surge in the stock price. The market reacted positively to the financing announcement, driving the stock price higher. ### Related Stocks - [LIQT.US](https://longbridge.com/en/quote/LIQT.US.md) - [MSTR.US](https://longbridge.com/en/quote/MSTR.US.md) - [NIVF.US](https://longbridge.com/en/quote/NIVF.US.md) - [CNTB.US](https://longbridge.com/en/quote/CNTB.US.md) - [LGHL.US](https://longbridge.com/en/quote/LGHL.US.md) ## Related News & Research - [Strategy Inc $MSTR Shares Bought by Partners Wealth Management LLC](https://longbridge.com/en/news/303729032.md) - [Strategy Q3 preview: Options market points to 4% stock swing after results](https://longbridge.com/en/news/303607781.md) - [MSTR Stock Is Down 44% in a Year, but Michael Saylor Says Strategy Doesn’t Need Bitcoin Or Equity to Do the ‘Heavy Lifting’](https://longbridge.com/en/news/303701275.md) - [Strategy’s preferred-stock fix sets up renewed bitcoin buying, analysts say](https://longbridge.com/en/news/303769363.md) - [Strategy Q3 revenue falls 3%, misses analyst estimates](https://longbridge.com/en/news/303622771.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**